INMED PHARMACEUTICALS INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
INMED PHARMACEUTICALS INC. (INM) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 748.53 thousand shares for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 2.65M shares, a 387.59% increase year-over-year.
- INMED PHARMACEUTICALS INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-09-30 was 543.33K shares, a 200.29% increase year-over-year.
- INMED PHARMACEUTICALS INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-09-30 was 180.93K shares, a 88.50% decline year-over-year.
- INMED PHARMACEUTICALS INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2022-09-30 was 1.57M shares.
- INMED PHARMACEUTICALS INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 3.62M shares, a 545.44% increase from fiscal 2022.
- INMED PHARMACEUTICALS INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 560.73K shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 748.53K shares S-4/A · filed 2026-09-09 | ||||||
| 2026-03-31 | 2.77M shares S-4 · filed 2026-07-02 | ||||||
| 2025-12-31 | 2.79M shares 10-Q · filed 2026-02-11 | ||||||
| 2025-09-30 | 2.65M shares 10-Q · filed 2025-11-06 | ||||||
| 2025-06-30 | 2.65M shares S-4/A · filed 2026-09-09 | ||||||
| 2025-03-31 | 571.44K shares S-4 · filed 2026-07-02 | ||||||
| 2024-12-31 | 572.00K shares 10-Q · filed 2026-02-11 | ||||||
| 2024-09-30 | 543.33K shares 10-Q · filed 2025-11-06 | ||||||
| 2024-06-30 | 543.30K shares S-4 · filed 2026-07-02 | 10.87M shares 10-K · filed 2024-09-30 | |||||
| 2024-03-31 | 694.13K shares 10-Q · filed 2025-05-12 | ||||||
| 2023-12-31 | 512.92K shares 10-Q · filed 2025-02-12 | 10.26M shares 10-Q · filed 2024-02-13 | |||||
| 2023-09-30 | 180.93K shares 10-Q · filed 2024-11-14 | 3.62M shares 10-Q · filed 2023-11-14 | |||||
| 2023-06-30 | 3.62M shares 10-K · filed 2024-09-30 | ||||||
| 2022-12-31 | 3.56M shares 10-Q · filed 2024-02-13 | ||||||
| 2022-09-30 | 1.57M shares 10-Q · filed 2023-11-14 | ||||||
| 2022-06-30 | 560.73K shares 10-K · filed 2023-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |